Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience
- 87 Downloads
We would like to address several challenges that have arisen from the study by Blanc et al.  which can be specifically summarized below.
The study was retrospectively conducted with a small sample size of retinal vein occlusions (RVO) divided into two groups with unbalanced numbers of patients, namely, group 1 including patients who received dexamethasone (DEX) implant injections only (Ozurdex, Allergan, Inc., CA, USA) and group 2 with patients who received DEX implants first and then were switched to anti-vascular endothelial growth factor (VEGF) agents.
There was a selection bias attributable to inclusion in the study and pooled analysis of patients with two forms of RVOs (ischemic and nonischemic occlusions) having totally different pathogenesis, clinical features, prognoses, and management. Likewise, the inclusion in the study of two types of RVOs (branch and central retinal vein) was inappropriate because they have different etiology, pathogenesis, and prognosis [2...
Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Blanc J, Deschasse C, Kodjikian L, Dot C, Bron AM, Creuzot-Garcher C (2018) Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-018-4016-7. Published online: May 31, 2018CrossRefGoogle Scholar